[ad_1] The turnaround at Teva Pharmaceutical Industries remains on schedule. The generic drug giant reported third-quarter sales of $4.5 billion and adjusted earnings of 68 cents a share. While both figures were …
Read More »Teva Passes Its Check-Up – WSJ
